The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
Open accessAbstract
Glucagon-like peptide 1 (GLP-1) is a growth factor. GLP-1 mimetics are on the market as treatments for type 2 diabetes and are well tolerated. These drugs have shown neuroprotective properties in animal models of neurodegenerative disorders. In addition, the GLP-1 mimetic exendin-4 has shown protective effects in animal models of Parkinson's disease (PD), and a clinical trial in PD patients showed promising first results. Liraglutide and lixisenatide are two newer GLP-1 mimetics which have a longer biological half-life than exendin-4. We previously showed that these drugs have neuroprotective properties in an animal model of Alzheimer's disease. Here we demonstrate the neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD. MPTP was injected once-daily (20mg/kg i.p.) for 7 days, and drugs were injected once-daily for 14 days i.p. When comparing exendin-4 (10 nmol/kg), liraglutide (25 nmol/kg) and lixisenatide (10 nmol/kg), it was found that exendin-4 showed no protective effects at the dose chosen. Both liraglutide and lixisenatide showed effects in preventing the MPTP-induced motor impairment (Rotarod, open-field locomotion, catalepsy test), reduction in tyrosine hydroxylase (TH) levels (dopamine synthesis) in the substantia nigra and basal ganglia, a reduction of the pro-apoptotic signaling molecule BAX and an increase in the anti-apoptotic signaling molecule B-cell lymphoma-2. The results demonstrate that in this study, both liraglutide and lixisenatide are superior to exendin-4, and both drugs show promise as a novel treatment of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Regarding Parkinson disease, earlier GLP-1RAs, such as liraglutide and lixisenatide, have been shown to protect dopaminergic neurons and reduce motor disability in animal models.32”
From Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity (2025) · cites this paper as [32]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Researchers have discovered that GLP-1RAs exhibit a noticeable increase in the level of phosphorylated ERK1/2 within the sciatic nerve of diabetic rats.”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [401]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Self-citationIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 645
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
Self-citationInteractions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
McClean, P. L., & Hölscher, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 362
Self-citationEntry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V. L. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 358
Cited by
Sorted by citations
Items 101–200 of 246
Hansen, H. H., Fabricius, K., Barkholt, P., Mikkelsen, J. D., Jelsing, J., Pyke, C., Knudsen, L. B., & Vrang, N. (2016) · Brain Research · doi:10.1016/j.brainres.2016.05.038 · Cited by 40
Modulation of Autophagy by a Small Molecule Inverse Agonist of ERRα Is Neuroprotective
Suresh, S., Chavalmane, A. K., Pillai, M. S., Ammanathan, V., Vidyadhara, D. J., Yarreiphang, H., Rai, S., Paul, A., Clement, J. P., Alladi, P. A., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00109 · Cited by 39
Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson′s disease
Yu, H., Sun, T., Wang, Z., Li, H., Xu, D., An, J., Wen, L.-L., Li, J., Li, W., & Feng, J. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.360242 · Cited by 40
Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease
Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Lin, L., & Hölscher, C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.038 · Cited by 38
Self-citationNovel Targets for Parkinson’s Disease: Addressing Different Therapeutic Paradigms and Conundrums
Rane, P., Sarmah, D., Bhute, S., Kaur, H., Goswami, A., Kalia, K., Borah, A., Dave, K. R., Sharma, N., & Bhattacharya, P. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00180 · Cited by 35
Wolak, M., Staszewska, T., Juszczak, M., Gałdyszyńska, M., & Bojanowska, E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.10.053 · Cited by 36
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 48
Wang, V., Kuo, T., Huang, E. Y., Ma, K., Chou, Y., Fu, Z.-Y., Lai, L.-W., Jung, J. H., Choi, H.-I., Choi, D., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00013 · Cited by 35
Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord
Lee, S.-O., Kuthati, Y., Huang, W.-H., & Wong, C. (2024) · Cells · doi:10.3390/cells13221857 · Cited by 43
Hong, G. U., Cho, J. W., Kim, S. Y., Shin, J. H., & Ro, J. Y. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.09.003 · Cited by 33
GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential
Moaket, O. S., Obaid, S. E., Obaid, F. E., Shakeeb, Y. A., Elsharief, S. M., Tania, A., Darwish, R., Butler, A. E., & Moin, A. S. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110743 · Cited by 40
Tackling dipeptidyl peptidase IV in neurological disorders
Castorina, A., Al‐Badri, G., Leggio, G. M., Musumeci, G., Marzagalli, R., & Drago, F. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.224365 · Cited by 34
Citraro, R., Iannone, M., Leo, A., Caro, C. D., Nesci, V., Tallarico, M., Abdalla, K., Palma, E., Arturi, F., Sarro, G. D., et al. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.08.001 · Cited by 33
Arbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 33
Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases
Plascencia‐Villa, G., & Perry, G. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512486 · Cited by 33
Pandey, S., Mangmool, S., Madreiter‐Sokolowski, C. T., Wichaiyo, S., Luangmonkong, T., & Parichatikanond, W. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175896 · Cited by 31
Park, S. W., Mansur, R. B., Lee, Y. L., Lee, J.-H., Seo, M. K., Choi, A. J., McIntyre, R. S., & Lee, J. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00756 · Cited by 33
Green, H., Tsitsi, P., Markaki, I., Aarsland, D., & Svenningsson, P. (2019) · CNS Drugs · doi:10.1007/s40263-018-0601-x · Cited by 31
Bougea, A. M. (2024) · Biomedicines · doi:10.3390/biomedicines12030549 · Cited by 30
Scala, C. D., Armstrong, N., Chahinian, H., Chabrière, É., Fantini, J., & Yahi, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113383 · Cited by 31
Li, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 28
Self-citationGuttuso, T. J., Andrzejewski, K. L., Lichter, D. G., & Andersen, J. K. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.05.016 · Cited by 29
McIntyre, R. S., Rasgon, N., Goldberg, J. F., Wong, S., Le, G. H., Mansur, R. B., Rosenblat, J. D., Teopiz, K. M., & Stahl, S. M. (2025) · CNS Spectrums · doi:10.1017/s1092852925000124 · Cited by 32
Labandeira, C. M., Bau, A. F., Ron, D. A., Muñoz, A., Losada, G. A., Koukoulis, A., Romero-López, J., & Rodriguez-Perez, A. I. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100914 · Cited by 28
Qi, L., Gao, R., Chen, Z., Lin, D., Liu, Z., Wang, L., Liu, X., Liu, X., Liu, X., & Liu, L. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.08.007 · Cited by 28
Bhalla, S., & Mehan, S. (2022) · Neuropeptides · doi:10.1016/j.npep.2022.102296 · Cited by 29
Liu, W., Wang, Z., Wang, W., Wang, Z., Xing, Y., & Hölscher, C. (2024) · Neurochemical Research · doi:10.1007/s11064-023-04093-6 · Cited by 28
Self-citationThe promise of GLP-1 receptor agonists for neurodegenerative diseases
Athauda, D. S., Greig, N. H., Meissner, W. G., Foltynie, T., & Gandhi, S. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194745 · Cited by 31
Su, Y., Zhang, Z., Li, H., Ma, J., Sun, L., Shao, S., Zhang, Z., & Hölscher, C. (2020) · Drug Research · doi:10.1055/a-1266-3263 · Cited by 27
Self-citationDrug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
Stott, S., Wyse, R. K. H., & Brundin, P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.653377 · Cited by 30
Semaglutide Protects against 6‐OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress
Liu, D.-X., Zhao, C.-S., Wei, X., Ma, Y.-P., & Wu, J.-K. (2022) · Parkinson s Disease · doi:10.1155/2022/6813017 · Cited by 27
Recent research progress on metabolic syndrome and risk of Parkinson’s disease
Li, L., Liu, S., Zhuang, J.-L., Li, M.-M., Huang, Z., Chen, Y., Chen, X., Chen, C., Lin, S., & Ye, L. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0093 · Cited by 30
Self-citationBehavioral analysis of motor and non-motor impairment in rodent models of Parkinson's disease
Sheta, R., Bérard, M., Musiol, D., Martínez-Drudis, L., & Oueslati, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1464706 · Cited by 26
Liu, C., Wang, W., Li, H., Liu, J., Zhang, P., Cheng, Y., Qin, X., Hu, Y., & Wei, Y. (2021) · Food & Function · doi:10.1039/d1fo00843a · Cited by 26
Daidzein alleviates neuronal damage and oxidative stress via GSK3β/Nrf2 pathway in mice
Wang, X., Yin, Z., Meng, X., Yang, D., Meng, H., Liao, C., Wei, L., Chen, Y., Yang, X., Han, J., et al. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105060 · Cited by 26
Abdellatif, R., Heeba, G. H., Taye, A., & Khalifa, M. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.045 · Cited by 26
Chou, C., & Chuang, S. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13314 · Cited by 25
Zhang, H., Chu, Y., Zheng, H., Wang, J., Song, B., & Sun, Y. (2020) · Aging · doi:10.18632/aging.202162 · Cited by 25
el‐Rady, N. M. A., Ahmed, A., Abdel‐Rady, M. M., & Ismail, O. I. (2020) · Physiological Reports · doi:10.14814/phy2.14651 · Cited by 30
Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders
Khatri, D. K., Kadbhane, A., Patel, M., Nene, S., Atmakuri, S., Srivastava, S., & Singh, S. B. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100022 · Cited by 25
Zhang, Z., Li, H., Su, Y., Ma, J., Yuan, Y., Yu, Z., Shi, M., Shao, S., Zhang, Z., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.814430 · Cited by 26
Self-citationOld wines in new bottles: Repurposing opportunities for Parkinson's disease
Kakkar, A. K., Singh, H., & Medhi, B. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.023 · Cited by 25
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 30
Hölscher, C. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000087 · Cited by 25
Self-citationRen, G., Xue, P., Wu, B., Yang, F., & Wu, X. (2021) · Aging · doi:10.18632/aging.202358 · Cited by 24
Keerie, A. F. A., Brown-Wright, H., Kirkland, I., Grierson, A. J., Alix, J. J. P., Hölscher, C., & Mead, R. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-96418-0 · Cited by 24
Self-citationMyeloid cells in retinal and brain degeneration
Guo, M., Schwartz, T. D., Dunaief, J. L., & Cui, Q. N. (2021) · FEBS Journal · doi:10.1111/febs.16177 · Cited by 25
Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Tanvir, A., Jo, J., & Park, S. M. (2024) · Cells · doi:10.3390/cells13221876 · Cited by 52
Hölscher, C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01226-z · Cited by 26
Self-citationTian, M.-J., Wang, R., Hölscher, C., Mi, R., Yuan, Z., Li, D., & Xue, G. (2019) · Epilepsy Research · doi:10.1016/j.eplepsyres.2019.05.008 · Cited by 21
Self-citationMorén, C., Treder, N., Martínez-Pinteño, A., Rodríguez, N., Arbelo, N., Madero, S., Gómez, M., Mas, S., Gassó, P., & Parellada, E. (2022) · Antioxidants · doi:10.3390/antiox11112275 · Cited by 22
Clinical Trial Highlights – GLP-1 agonists
McFarthing, K., Larson, D., & Simuni, T. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-200002 · Cited by 20
Incretin-based therapeutics for the treatment of neurodegenerative diseases
Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 25
Olukorode, J., Orimoloye, D. A., Nwachukwu, N. O., ONWUZO, C. N., Oloyede, P. O., Fayemi, T., Odunaike, O. S., Ayobami-Ojo, P. S., Divine, N., Alo, D. J., et al. (2024) · Cureus · doi:10.7759/cureus.72080 · Cited by 26
Gad, S. N., Nofal, S., Raafat, E. M., & Ahmed, A. A. E. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01497-9 · Cited by 18
Wyse, R. K. H., Isaacs, T., Barker, R. A., Cookson, M., Dawson, T. M., Devos, D., Dexter, D. T., Duffen, J., Federoff, H. J., Fiske, B. K., et al. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230363 · Cited by 19
Vilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.06.017 · Cited by 21
Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease
Verma, A., & Goyal, A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176936 · Cited by 17
Girges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
Meng, H.-W., Shen, Z.-B., Meng, X.-S., Leng-Wei, Yin, Z., Wang, X., Zou, T., Liu, Z., Wang, T., Zhang, S., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106654 · Cited by 16
He, W., Tian, X., Lv, M., & Wang, H. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2018.05.039 · Cited by 16
Liraglutide Treatment Ameliorates Neurotoxicity Induced by Stable Silencing of Pin1
Bianchi, M., Doria, V., Braghini, M. R., Petrini, S., & Manco, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205064 · Cited by 17
Shang, P., Baker, M. R., Banks, S. A., Hong, S., & Choi, D. (2021) · Journal of Movement Disorders · doi:10.14802/jmd.21035 · Cited by 16
Zhang, Z., Shi, M., Li, Z., Ling, Y., Zhai, L., Yuan, Y., Ma, H., Li, H., Li, Z., Zhang, Z., et al. (2023) · Parkinson s Disease · doi:10.1155/2023/7427136 · Cited by 16
Self-citationProtective Effects of Incretin Against Age-Related Diseases
Zhang, D., Ma, M., & Liu, Y. (2019) · Current Drug Delivery · doi:10.2174/1567201816666191010145029 · Cited by 15
Victorino, D. B., Nejm, M. B., Guimarães‐Marques, M., Scorza, F. A., & Scorza, C. A. (2021) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00374-5 · Cited by 15
Novel approaches to counter protein aggregation pathology in Parkinson's disease
Stott, S., Wyse, R. K. H., & Brundin, P. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.007 · Cited by 16
Age-related change of GLP-1R expression in rats can be detected by [18F]AlF-NOTA-MAL-Cys39-exendin-4
Wang, L., Liu, Y., Xu, Y., Sheng, J., Pan, D., Wang, X., Yan, J., Yang, R., & Yang, M. (2018) · Brain Research · doi:10.1016/j.brainres.2018.08.022 · Cited by 14
Dahiya, S., Tisch, S. H., & Greenfield, J. R. (2022) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2022.100133 · Cited by 13
The Contribution of Type 2 Diabetes to Parkinson’s Disease Aetiology
Ribarič, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084358 · Cited by 15
Riemma, M. A., Mele, E., Donniacuo, M., Telesca, M., Bellocchio, G., Castaldo, G., Rossi, F., Angelis, A. D., Cappetta, D., Urbanek, K., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1422740 · Cited by 13
Pradeloux, S., Coulombe, K., Ouamba, A. J. K., Isenbrandt, A., Calon, F., Roy, D., & Soulet, D. (2024) · Nutrients · doi:10.3390/nu16193309 · Cited by 13
Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson’s Disease
Jeong, S. H., & Lee, P. H. (2025) · Journal of Movement Disorders · doi:10.14802/jmd.25008 · Cited by 13
Recent Advances in Drug Repurposing for Parkinson’s Disease
Chen, X., Gumina, G., & Virga, K. G. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180719144850 · Cited by 13
Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Luo, Y., Xia, Y., Gong, X., Hao, M., Wei, Q., & Liao, L. (2026) · BMC Ophthalmology · doi:10.1186/s12886-025-04559-x · Cited by 15
Dhureja, M., & Deshmukh, R. R. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176635 · Cited by 11
Khalaf, M. M., El-Sayed, M. M., Kandeil, M. A., & Ahmed, S. A. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110170 · Cited by 11
Antidiabetic drugs in Parkinson’s disease
Aguirre-Vidal, Y., Montes, S., Mota-López, A. C., & Navarrete‐Vázquez, G. (2024) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2024.100265 · Cited by 10
Glucagon-like Peptide 1, Brain, Neurodegenerative Diseases: A Modern View
Bulgakova, Romanchuk, N., & Treneva, E. V. (2020) · Bulletin of Science and Practice · doi:10.33619/2414-2948/53/19 · Cited by 10
Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases
Hölscher, C. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.01.007 · Cited by 10
Self-citationAn update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
Salvadè, M., Luca, M. D., & Gardoni, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117862 · Cited by 12
GLP-1 agonists: a game changer in pain treatment and addiction
Bade, S., Hurdle, M. F. B., Bade, S., Encalada, S., Kanahan-Osman, S., & Gupta, S. (2025) · Pain Management · doi:10.1080/17581869.2025.2536998 · Cited by 11
Glucagon-like peptide-1 medicines in neurological and psychiatric disorders
Fang, S., Cui, F., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102511 · Cited by 9
Vilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.10.019 · Cited by 8
Interactions between antidiabetes medications and heart–brain axis
Ong, L. T., & Sia, C. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000896 · Cited by 8
Giofrè, F., Zaffina, I., Pelle, M. C., & Arturi, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1696419 · Cited by 9
Mitral cells and the glucagon‐like peptide 1 receptor: The sweet smell of success?
Bagnoli, E., & FitzGerald, U. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14115 · Cited by 8
Athauda, D. S., Evans, J. R., Mahoney‐Sanchez, L., Virdi, G. S., Lopez-Garcia, P., Wernick, A. I., Wagen, A. Z., D’Sa, K., Lachica, J., Strohbuecker, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.28.582460 · Cited by 7
Poupon-Bejuit, L., Geard, A. F., Millicheap, N., Rocha‐Ferreira, E., Hagberg, H., Thornton, C., & Rahim, A. A. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00079-1 · Cited by 8
Parkinson’s disease and brain insulin signaling: Mechanisms and potential role of GLP-1 mimetics
Foroozanmehr, B., Hemmati, M. A., Yaribeygi, H., Karav, S., Jamialahmadi, T., & Sahebkar, A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149738 · Cited by 6
Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson’s disease
Lee, S. M. L., Yin, L., Xiao, N., Rhee, T. G., Lo, H. K. Y., Wong, S., Fox, S. H., Teopiz, K. M., Lam, B. Y., Zheng, Y. J., et al. (2025) · CNS Spectrums · doi:10.1017/s109285292510031x · Cited by 6
Badran, A., & Gbreel, M. I. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08411-4 · Cited by 6
De, S., Banerjee, S., Rakshit, P., Banerjee, S., & Kumar, S. K. A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998291968240429111357 · Cited by 6
Zhang, X., Du, P., Bai, B., Feng, P., Lian, X., Hölscher, C., Wang, Y., & Xue, G. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1596506 · Cited by 7
Self-citationYeh, J.-A., Lin, S., Liu, Y., Hsu, J.-Z., Huang, A. H., Munir, K. M., Peng, C. C., Loh, C., & Huang, H. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112914 · Cited by 6
García-Fernández, M. D., Larrea, A., Fernández, R., Rodríguez‐Puertas, R., Astigarraga, E., Manuel, I., & Barreda‐Gómez, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065470 · Cited by 6
Glucagon-Like Peptide-1 Receptor Agonists in Neurodegenerative Diseases: A Comprehensive Review
Ibrahim, R., Kambal, A., & Abdelmajeed, M. A. (2025) · Cureus · doi:10.7759/cureus.92441 · Cited by 5
GLP-1 Signalling as a Therapeutic Avenue in Parkinson’s Disease: A Comprehensive Review
Orozco, M. P., Rivadeneira, V. V., & León-Rojas, J. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412163 · Cited by 7
Microglia heterogeneity and therapeutic strategies in Parkinson’s disease
Tian, J., Liu, X., Wang, Z., Shi, X., Dai, C., & Yang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1739341 · Cited by 6
Metadata
- Authors
- Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C.
- Affiliations
- Shanxi Medical University (CN)
- Lancaster University (GB)
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 303
- Pages
- 42-50
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W2211963426
- Cited by
- 246
- References
- 38
- Citations by year
- 2026: 24 · 2025: 27 · 2024: 32 · 2023: 15 · 2022: 33 · 2021: 20 · 2020: 16 · 2019: 17 · 2018: 27 · 2017: 11 · 2016: 16 · 2015: 7
- FWCI
- 14.33
- Type
- journal article
- Language
- en
- Open access
- green
- eprints.lancs.ac.uk
- Locations
- Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Lancaster EPrints (Lancaster University) (submittedVersion)
- Funders
- Cure Parkinson’s Trust, UK
- Shanxi Province Government, China
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, liraglutide, lixisenatide, GLP-1 receptor agonists, neuroprotection, MPTP mouse model, exendin-4, dopamine synthesis, substantia nigra, Bax, Bcl-2, apoptosis, motor impairment, catalepsy
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Liraglutide, Exenatide, Animals, Basal Ganglia, Catalepsy, Disease Models, Animal, Male, Mice, Inbred C57BL, Motor Activity, Peptides, Substantia Nigra, Tyrosine 3-Monooxygenase, Venoms, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Apoptosis, Neuroprotective Agents, Parkinsonian Disorders, Rotarod Performance Test, Mice, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
